Scotiabank analyst Greg Harrison raised the firm’s price target on BridgeBio (BBIO) to $49 from $48 and keeps an Outperform rating on the ...

Shares of BridgeBio Pharma (NASDAQ:BBIO), currently valued at $5.88 billion, witnessed an uptick as Scotiabank (TSX:BNS) analyst Greg Harrison increased the price target to $49 from $48 while ...

The EU is the second market for the drug after the US, where it was approved under the Attruby brand name last November, on ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.BoQAct6R.js ...

The German drugmaker confirmed acquisition talks, but cautioned a deal may not materialize. Elsewhere, Biohaven got priority review on a key drug and Third Harmonic restructured.

The European Commission has granted marketing authorization in the European Union (EU) for acoramidis, under the brand name ...

The approval is based on positive results from the Phase 3 ATTRibute-CM study, in which acoramidis demonstrated the most ...

H.C. Wainwright maintained its optimistic stance on Immix Biopharma , Inc. (NASDAQ:IMMX), with analyst Robert Burns reiterating a Buy rating and a $7.00 price target on the company's shares. Currently ...

Prothena (NASDAQ:PRTA – Free Report) had its price target boosted by Oppenheimer from $58.00 to $62.00 in a report published on Friday,Benzinga reports. They currently have an outperform rating on the ...

Immix Biopharma (IMMX) announced that the U.S. FDA has granted RMAT designation to sterically-optimized CAR-T NXC-201 for the treatment of ...

Mayo Clinic recently announced separate generative artificial intelligence collaborations with Microsoft Research and ...

In a recent study of 35 World Trade Center first responders in the Journal of Alzheimer’s Disease, lead author Sean Clouston, ...